Roche H1 Sales Decline on Currency Headwinds, Key Drugs Keep Momentum – July 23, 2026
Key Takeaways Roche delivered 6% constant-currency sales growth in H1 2026, driven by Pharmaceuticals and Diagnostics. RHHBY’s growth…
Zacks Industry Outlook Highlights Mitsubishi UFJ Financial, UBS and KB Financial – August 11, 2026
For Immediate Release Chicago, IL – August 11, 2026 – Today, Zacks Equity Research discusses Mitsubishi UFJ Financial…
Alps Group Inc Reports Fiscal Year 2026 Financial Results and Provides Business Update
Revenue Grew 44% to $4.9 Million, Led by Continued Growth Across Cellular Therapy, Medical Testing, Laboratory and Aesthetics…
Alps Group Inc Reports Fiscal Year 2026 Financial Results and Provides Business Update
Revenue Grew 44% to $4.9 Million, Led by Continued Growth Across Cellular Therapy, Medical Testing, Laboratory and Aesthetics…
Buy 2 SS&C ALPS Mutual Funds for Risk-Adjusted Returns – August 7, 2026
SS&C ALPS Advisors is a U.S.-based asset management company offering a broad range of mutual funds that fall…
Chubb’s Solid Growth Comes With a Premium Valuation – Hold or Buy? – August 3, 2026
Key Takeaways Chubb benefits from broad premium growth across commercial, personal, agriculture and life businesses. Strategic acquisitions and…
Top Stock Reports for Micron Technology, Roche & UnitedHealth – January 7, 2026
Wednesday, January 7, 2026 The Zacks Research Daily presents the best research output of our analyst team. Today’s…
UBS Group Q2 Earnings & Revenues Increase Y/Y Despite Higher Expenses – July 29, 2026
Key Takeaways UBS reported Q2 net profit attributable to shareholders of $2.80 billion, up from $2.39 billion a…
The Zacks Analyst Blog Highlights Apple, Microsoft, Amazon, LVMH, AstraZeneca, Shell, Airbus and UBS – July 28, 2026
For Immediate Release Chicago, IL – July 28, 2026 – Zacks.com announces the list of stocks featured in…
Novartis Q2 Earnings & Revenues Top Estimates, Key Drugs Perform Well – July 21, 2026
Key Takeaways Novartis beat Q2 earnings and revenue estimates as priority brands helped offset generic competition.NVS reaffirmed 2026…
Can Novartis’ Fabhalta Strengthen Its Nephrology Franchise? – July 17, 2026
Key Takeaways NVS secured full FDA approval for Fabhalta to slow kidney function decline in adults with primary…
The Zacks Analyst Blog Highlights SAP, UBS Group, Cadence, Village Super Market and Medalist Diversified – July 14, 2026
For Immediate Release Chicago, IL – July 14, 2026 – Zacks.com announces the list of stocks and ETFs…